Medicenna Therapeutics Corp. (MDNA.TO)

CAD 1.13

(13.0%)

Total Assets Summary of Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp.'s latest annual total assets in 2023 was 19.13 Million CAD , down -47.5% from previous year.
Medicenna Therapeutics Corp.'s latest quarterly total assets in 2024 Q1 was 38.02 Million CAD , up 98.73% from previous quarter.
Medicenna Therapeutics Corp. reported annual total assets of 36.44 Million CAD in 2022, up 55.38% from previous year.
Medicenna Therapeutics Corp. reported annual total assets of 23.45 Million CAD in 2021, down -44.49% from previous year.
Medicenna Therapeutics Corp. reported quarterly total assets of 19.13 Million CAD for 2023 FY, down -47.5% from previous quarter.
Medicenna Therapeutics Corp. reported quarterly total assets of 19.13 Million CAD for 2023 Q4, down -17.77% from previous quarter.

Annual Total Assets Chart of Medicenna Therapeutics Corp. (2023 - 2013)

Historical Annual Total Assets of Medicenna Therapeutics Corp. (2023 - 2013)

Year	Total Assets	Total Assets Growth
2023	19.13 Million CAD	-47.5%
2022	36.44 Million CAD	55.38%
2021	23.45 Million CAD	-44.49%
2020	42.25 Million CAD	11.2%
2019	37.99 Million CAD	632.47%
2018	5.18 Million CAD	18.58%
2017	4.37 Million CAD	-69.8%
2016	14.48 Million CAD	151.66%
2015	5.75 Million CAD	2011.45%
2014	272.56 Thousand CAD	-51.57%
2013	562.84 Thousand CAD	0.0%

Year	Total Assets	Total Assets Growth
2024 Q1	38.02 Million CAD	98.73%
2023 FY	19.13 Million CAD	-47.5%
2023 Q4	19.13 Million CAD	-17.77%
2023 Q3	23.26 Million CAD	-16.13%
2023 Q2	27.74 Million CAD	-12.06%
2023 Q1	31.54 Million CAD	-13.44%
2022 Q3	38.17 Million CAD	-10.31%
2022 FY	36.44 Million CAD	55.38%
2022 Q1	20.14 Million CAD	-14.14%
2022 Q2	42.56 Million CAD	111.32%
2022 Q4	36.44 Million CAD	-4.53%
2021 Q2	30.09 Million CAD	-19.4%
2021 Q1	37.33 Million CAD	-11.63%
2021 Q4	23.45 Million CAD	-10.15%
2021 Q3	26.1 Million CAD	-13.25%
2021 FY	23.45 Million CAD	-44.49%
2020 FY	42.25 Million CAD	11.2%
2020 Q4	42.25 Million CAD	16.32%
2020 Q3	36.32 Million CAD	-3.5%
2020 Q2	37.64 Million CAD	-8.01%
2020 Q1	40.91 Million CAD	7.69%
2019 FY	37.99 Million CAD	632.47%
2019 Q3	7.31 Million CAD	226.05%
2019 Q4	37.99 Million CAD	419.37%
2019 Q1	3.67 Million CAD	-29.17%
2019 Q2	2.24 Million CAD	-38.93%
2018 Q3	6.01 Million CAD	76.54%
2018 Q4	5.18 Million CAD	-13.8%
2018 FY	5.18 Million CAD	18.58%
2018 Q1	3.64 Million CAD	-16.69%
2018 Q2	3.4 Million CAD	-6.47%
2017 Q2	9.9 Million CAD	-20.55%
2017 Q1	12.46 Million CAD	-13.93%
2017 Q3	6.83 Million CAD	-30.95%
2017 FY	4.37 Million CAD	-69.8%
2017 Q4	4.37 Million CAD	-36.03%
2016 Q2	798.36 Thousand CAD	-0.57%
2016 Q1	802.91 Thousand CAD	-3.35%
2016 FY	14.48 Million CAD	151.66%
2016 Q4	14.48 Million CAD	147.52%
2016 Q3	5.85 Million CAD	632.93%
2015 Q2	865.66 Thousand CAD	69.28%
2015 Q4	830.77 Thousand CAD	0.0%
2015 Q1	511.39 Thousand CAD	0.0%
2015 FY	5.75 Million CAD	2011.45%
2014 FY	272.56 Thousand CAD	-51.57%
2013 FY	562.84 Thousand CAD	0.0%

Peer Total Assets Comparison of Medicenna Therapeutics Corp.

Name	Total Assets	Total Assets Difference
Appili Therapeutics Inc.	1.49 Million CAD	-1183.814%
Eupraxia Pharmaceuticals Inc.	26.72 Million CAD	28.399%
Helix BioPharma Corp.	1.48 Million CAD	-1185.024%
Microbix Biosystems Inc.	35.65 Million CAD	46.333%
Satellos Bioscience Inc.	44.29 Million CAD	56.806%
Oncolytics Biotech Inc.	38.82 Million CAD	50.711%
Sernova Corp.	22.1 Million CAD	13.448%